← All trials
NCT04468659
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 13, 2020
- Primary completion
- Oct 25, 2027
- Completion date
- Oct 25, 2027
- First posted
- Jul 13, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 1400
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EisaiLead sponsor
- BiogenCollaborator
- National Institute on Aging (NIA)Collaborator
- Alzheimer's Clinical Trial Consortium (ACTC)Collaborator
- Alzheimer's Clinical Trial Consortium (ACTC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.